Search results for "Highlights"
Update in Endocrinology highlights top diabetes research of 2013
Ten studies from 2013 with potential to change endocrinology practice were summarized in Annals of Internal Medicine's annual Update in Endocrinology, published in the June 3 issue.
https://diabetes.acponline.org/archives/2014/06/13/5.htm
13 Jun 2014
Recent KDIGO guideline focused on patients with diabetes and kidney disease
A new summary of the guideline from Kidney Disease: Improving Global Outcomes (KDIGO) highlights important points for clinicians, including recommendations about prescribing of diabetes medications.
https://diabetes.acponline.org/archives/2020/11/13/7.htm
13 Nov 2020
ADA position statement updates recommendations for diabetic retinopathy
The position statement, an update of one from 2002, outlines the stages of diabetic retinopathy and highlights recommendations on optimal blood glycemic control and lowering blood pressure.
https://diabetes.acponline.org/archives/2017/03/10/1.htm
10 Mar 2017
Statins provided primary prevention benefit in younger patients with type 1 diabetes
Researchers used a British database to conduct a target-trial emulation assessing the benefits of statin initiation in type 1 diabetes patients with a mean age of 45 years. They found significant decreases in 10-year risk of all-cause mortality and cardiovascular disease in those who took statins.
https://diabetes.acponline.org/archives/2025/09/12/3.htm
12 Sep 2025
Semaglutide, tirzepatide showed improved outcomes in patients with HF and diabetes
Risk for heart failure (HF) hospitalization or all-cause mortality was more than 40% lower in patients with type 2 diabetes and HF with preserved ejection fraction who took semaglutide or tirzepatide compared to those who took sitagliptin (a placebo proxy), a study found.
https://diabetes.acponline.org/archives/2025/09/12/2.htm
12 Sep 2025
New living guideline offers advice on medications for type 2 diabetes
The risk-stratified recommendations, developed by an international panel for the BMJ Rapid Recommendations series, are intended to help physicians and patients choose among sodium-glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, finerenone, and tirzepatide.
https://diabetes.acponline.org/archives/2025/09/12/1.htm
12 Sep 2025
Mixed findings on associations between tirzepatide and diabetic retinopathy
New-onset proliferative diabetic retinopathy occurred in 1.1% of patients on tirzepatide versus 0.5% of matched controls, but new onset of any retinopathy was less common in patients with diabetes who took tirzepatide and had no retinopathy at baseline, a retrospective study found.
https://diabetes.acponline.org/archives/2025/08/08/3.htm
8 Aug 2025
Type 2 diabetes remission more likely in patients taking fewer medications, study finds
Just 2.9% of more than 556,000 type 2 diabetes patients who did not undergo bariatric surgery achieved remission over three years, and 36.9% of them relapsed before the end of the three-year follow-up, according to analysis of data from six U.S. health systems.
https://diabetes.acponline.org/archives/2025/08/08/2.htm
8 Aug 2025
Guidance offered on handling pregnancy in patients with pre-existing diabetes
A new joint clinical practice guideline from the Endocrine Society and the European Society of Endocrinology suggests screening for pregnancy intent in diabetes patients and addresses use of glucagon-like peptide-1 receptor agonists, insulin, and continuous glucose monitoring before and during pregnancy.
https://diabetes.acponline.org/archives/2025/08/08/1.htm
8 Aug 2025
Fenofibrate cost-effective for preventing diabetic retinopathy progression
In diabetes patients with mild background retinopathy in both eyes or observable background retinopathy or maculopathy in one or both eyes, treatment with fenofibrate reduced the need for any referable diabetic retinopathy or treatment by 4.4% over two years, an analysis of a randomized trial found.
https://diabetes.acponline.org/archives/2025/07/11/3.htm
11 Jul 2025
Mifepristone improved diabetes control in hypercortisolism, industry trial finds
Patients with poorly controlled type 2 diabetes and hypercortisolism assigned to mifepristone versus placebo had lower HbA1c levels and greater reductions in body mass index and waist circumference at 24 weeks, although adverse events were common.
https://diabetes.acponline.org/archives/2025/07/11/2.htm
11 Jul 2025
Semaglutide associated with lower stroke risk than empagliflozin
An analysis of observational data found better outcomes with semaglutide than empagliflozin, particularly in patients younger than age 65 years. Outcomes with dulaglutide were similar to those with empagliflozin.
https://diabetes.acponline.org/archives/2025/07/11/1.htm
11 Jul 2025
Diabetes progression linked with increased risk of kidney cancer
Kidney cancer risk was significantly higher in patients with prolonged duration of diabetes, those with diabetic retinopathy or nephropathy, and those with poor glycemic control, a cohort study in South Korea found.
https://diabetes.acponline.org/archives/2025/06/13/3.htm
13 Jun 2025
Renal outcomes better with finerenone plus empagliflozin in type 2 diabetes and CKD
Patients with type 2 diabetes and chronic kidney disease (CKD) had a greater reduction in urinary albumin-to-creatinine ratio if they took finerenone plus empagliflozin versus either drug alone, an industry trial found.
https://diabetes.acponline.org/archives/2025/06/13/2.htm
13 Jun 2025
ADA consensus report calls for MASLD, liver fibrosis screening in type 2 diabetes
A two-tier system for stratifying patients based on their risk of metabolic dysfunction-associated steatotic liver disease (MASLD) was recommended by the American Diabetes Association (ADA).
https://diabetes.acponline.org/archives/2025/06/13/1.htm
13 Jun 2025
Studies examine prescribing patterns, access issues with newer diabetes drug classes
Use of tirzepatide, glucagon-like peptide-1 receptor agonists, and sodium-glucose cotransporter-2 inhibitors increased sharply in the U.S. from 2021 to 2023, one study found, while another noted inequities in availability of newer medications for type 2 diabetes.
https://diabetes.acponline.org/archives/2025/05/09/3.htm
9 May 2025
Standard care noninferior to acellular, cellular matrix products for diabetic foot ulcers
Researchers found no clinically significant differences in ulcer healing between the treatment types but found that acellular matrix products were more cost-effective than cellular matrix products and should thus be considered if standard care fails.
https://diabetes.acponline.org/archives/2025/05/09/2.htm
9 May 2025
Alternative measures didn't help in conditions thought to affect accuracy of HbA1c level
Using fructosamine or glycated albumin did not improve overall accuracy of glycemic measurement in an African population overall or in patients with sickle cell trait, anemia, or renal impairment, according to a comparison of these measures with HbA1c level and continuous glucose monitoring.
https://diabetes.acponline.org/archives/2025/05/09/1.htm
9 May 2025
Gastric bypass increased diabetes remission versus sleeve gastrectomy, small trial finds
At five years after gastric bypass, half of patients with type 2 diabetes and obesity had an HbA1c level less than 6%, compared to 20% of those randomized to sleeve gastrectomy, according to a secondary analysis of a Norwegian trial.
https://diabetes.acponline.org/archives/2025/04/11/3.htm
11 Apr 2025
Switching to tirzepatide improves outcomes vs. escalating dulaglutide in type 2 diabetes
An industry-funded randomized trial found that switching to tirzepatide after inadequate response to dulaglutide led to significant additional reductions in HbA1c levels and weight at 40 weeks compared with increasing the dulaglutide dose.
https://diabetes.acponline.org/archives/2025/04/11/2.htm
11 Apr 2025